Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 39(3); 2015 > Article
Original Article
Others Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
Sunghwan Suh1, Gi Hyeon Seo2, Chang Hee Jung3, Mee-Kyoung Kim4, Sang-Man Jin5, You-Cheol Hwang6, Byung-Wan Lee7, Jae Hyeon Kim5
Diabetes & Metabolism Journal 2015;39(3):247-252.
DOI: https://doi.org/10.4093/dmj.2015.39.3.247
Published online: April 22, 2015
  • 4,041 Views
  • 35 Download
  • 21 Web of Science
  • 18 Crossref
  • 20 Scopus

1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea.

2Health Insurance Review and Assessment Service, Seoul, Korea.

3Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

4Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

5Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

6Division of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.

7Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Jae Hyeon Kim. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. jaehyeon@skku.edu
• Received: June 13, 2014   • Accepted: August 8, 2014

Copyright © 2015 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • Background
    We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database.
  • Methods
    We collected data on newly prescribed sitagliptin, vildagliptin, and pioglitazone between January 1, 2009 and December 31, 2012 (mean follow-up of 336.8 days) to 935,519 patients with diabetes (518,614 males and 416,905 females) aged 40 to 79 years (mean age of 59.4 years).
  • Results
    During the study, 998 patients were hospitalized for primary HF (115.7 per 100,000 patient-years). The incidence rate of hospitalization for HF was 117.7 per 100,000 per patient-years among patients on pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin. The hospitalization rate for HF was greatest in the first 30 days after starting the medication, which corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs. The hazard ratios were 1.85 (pioglitazone), 2.00 (sitagliptin), and 1.79 (vildagliptin). The incidence of hospitalization for HF did not differ between the drugs for any time period.
  • Conclusion
    This study showed an increase in hospitalization for HF in the initial 30 days of the DPP4i and pioglitazone compared with the subsequent follow-up period. However, the differences between the drugs were not significant.
A major development in the pathogenesis of cardiovascular diseases (CVDs) is the understanding that patients with diabetes mellitus are more likely to develop coronary heart diseases and even more pronounced morbidity and mortality than nondiabetic patients [1]. CVD is best prevented in patients with diabetes by controlling the underlying condition, i.e., hyperglycemia. However, about half of patients with diabetes still do not achieve or maintain sufficient glycemic control to avoid substantial long-term morbidity [234].
New types of glucose-lowering agents are required for type 2 diabetes mellitus (T2DM) because a multivariable mix of genetic and environmental factors combine to create a progressive and highly heterogeneous natural history, with at least eight major organ systems being implicated [5]. However, increased risk of CVD, such as myocardial infarction [6] and heart failure (HF) [7], caused by thiazolidinediones (TZDs) has generated concerns of cardiovascular (CV) safety in developing novel drugs for T2DM. The Food and Drug Administration, therefore, mandated that all new glucose-lowering medications undergo a thorough CV safety assessment before market approval [8]. As a consequence, large-scale trials focused on longer-term CV outcomes have been initiated with most of the newer drugs. Recent results from large outcome trial of saxagliptin in patients with prior CVD or multiple CV risk factors (saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction [SAVOR-TIMI 53]) showed that saxagliptin did not increase or decrease the rate of ischemic events. However, more patients in the saxagliptin group than in the placebo group were hospitalized for HF [9]. This unexpected result caused controversy and uncertainty about the use of other dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP4i) [10], even though their longterm CV outcome studies are not finished or planned yet.
Therefore, we aimed to assess the association of DPP4i (sitagliptin and vildagliptin) and TZD (pioglitazone) with the HF hospitalization using the Korean Health Insurance claims database.
The study was performed in accordance with the Declaration of Helsinki and the guidelines for Good Pharmacoepidemiology Practices. All study protocols were approved by the Institutional Review Board (IRB) of Dong-A Medical Center. Informed consent was waived by the IRB.
Study population
Patients were identified from the Korean Health Insurance Review and Assessment Service database (HIRA), which contains medical claims data for the entire Korean population [11] as a result of the National Health Insurance System (NHIS). Patients pay an average of 30% of the total medical costs related to almost all diseases. Healthcare providers submit reports concerning the medical services performed to the HIRA for a review of the medical costs incurred. These reports contain diagnosis codes in accordance with the International Classification of Diseases 10th revision (ICD-10) as well as outpatient or inpatient status, drug name, dosage, prescription date, duration, and method of administration. The HIRA provided data with the individual identifiers removed, in accordance with the Act on the Protection of Personal Information maintained by public agencies. Thus, the database included an unidentifiable code representing each individual with the patient's age, gender, diagnosis, and a list of prescribed drugs. The database contained information collected from January 1, 2007 to December 31, 2012. HIRA data before 2007 was deleted and inaccessible in accordance with the Act on the Protection of Personal Information.
Definitions
Diabetic patients between the ages of 40 to 79 who began treatment with one of the three drugs from January 1, 2009 to December 31, 2012 were identified. Use of pioglitazone, sitagliptin, or vildagliptin was defined as receipt of a prescription for the drug during the study period. We only included the patients who were newly prescribed with these drugs by excluding patients with any prior prescription in 2007 or 2008. Pioglitazone, sitagliptin, and vildagliptin were launched in the Republic of Korea in January 2003, December 2008, and February 2009, respectively. Among them, patients who had been hospitalized with a principal discharge diagnosis of HF [12] were identified by using the ICD-10 codes I50. Patients hospitalized with a first diagnosis with HF were recruited by eliminating patients with a prior diagnosis of HF in 2007 or 2008. All hospitalizations for HF that occurred before medication was initiated were also excluded.
Statistical analysis
Data were analyzed using R program version 2.15.3. Values are presented as mean±standard deviation or numbers (%). For all statistical analyses a P value of less than 0.05 (two-sided) was considered to be statistically significant. We used a poisson regression to model the relationship and generate hazard ratios (HRs) and 95% confidence intervals comparing the days 0 to 30 with days 31 to 360 after TZD or DPP4i prescription [13]. A Cox regression model was used to examine whether the specific medication played a role in the hospitalization for HF. Age and sex were included as covariates in this model.
The database contained information regarding 935,519 patients with diabetes (518,614 males and 416,905 females) age 40 to 79 years (mean of 59.4 years) with prescriptions from January 1, 2009 to December 31, 2012 (mean follow-up of 336.8 days). Baseline characteristics are displayed in Table 1. A total of 25.0% patients took pioglitazone, 51.4% took sitagliptin, and 23.6% took vildagliptin. From 2009 to 2012, these subjects had 998 hospitalizations for primary HF (115.7 per 100,000 patientyears). The incidence of hospitalization for HF was 117.7 for pioglitazone, 105.7 for sitagliptin, and 135.8 for vildagliptin per 100,000 patient-years. The incidence according to time interval is depicted in Table 2. The rate of hospitalization for HF was greatest in the first 30 days after medication, and corresponded to a significantly higher incidence at days 0 to 30 compared with days 31 to 360 for all three drugs (Table 3). The HR was 1.85 for pioglitazone, 2.00 for sitagliptin, and 1.79 for vildagliptin. The incidence of hospitalization for HF did not differ among drugs at any time period, as shown in Table 4.
We observed a 1.8- to 2.0-fold increase in hospitalization for HF in the initial 30 days of the medication (pioglitazone, sitagliptin, and vildagliptin) compared with the subsequent followup period. We did not find a significant difference between the drugs.
Our finding of significantly higher hospitalization for HF in the first 30 days of treatment is novel and suggests a drug effect on the outcome. We did not include saxagliptin in this study because it was prescribed to too few patients (less than 3%). Instead, we chose sitagliptin and vildagliptin as comparators because they were the first two DPP4i released in the market and have the longest and largest prescription histories. However, studies of their long-term CV outcomes have not been finished or planned. We did not have control group to compare and verify causal relationships. Instead, we have chosen pioglitazone as comparator for the analysis which is known to increase the risk of edema and HF [7]. As expected, pioglitazone increased the risk of hospitalization for HF in 30 days even though doctors may not have prescribed the drug to patients at high risk for HF because TZD is well known risk factor. Sitagliptin and vildagliptin showed similar increase in the first 30 days of medication compared to pioglitazone. In addition, there was no significant difference between sitagliptin and vildagliptin in the key outcome (data not shown). There might be some possibility that hidden HF affected the result of increased hospitalization in the initial 30 days. However, we eliminated those with a prior diagnosis of HF to reduce these possibilities. All these results indicate a class effect and relatively acute drug effect on HF. To date, there is no published data on prescription days before HF hospitalization for SAVOR-TIMI 53. We recommend further analysis of this outcome for the already published long-term CV outcome studies.
The most recent article on sitagliptin found significant increased risk of HF-related hospitalizations among patients with T2DM and HF [14]. The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial [15] had more CV deaths in the treatment arm than in the placebo arm. Moreover, there was a statistically significant increase in left ventricular end-diastolic volume and a trend toward increased left ventricular end-systolic volume. In the meantime, a meta-analysis of randomized clinical trials of DPP4i [16] and 20 phase 2 and 3 trials of saxagliptin [17] assessed CV risk. The latter concluded that saxagliptin was not associated with an increased risk of CV, including HF. Furthermore, the former report found that DPP4i treatment reduces the risk of CVD (particularly myocardial infarction) and all-cause mortality in patients with T2DM. However, both studies lack of long-term CV outcome data. Recently, a meta-analysis [18] of DPP4i and HF (including results from SAVOR-TIMI 53) suggested that DPP4i could be associated with an increased risk of HF, without any clear evidence of differences among drugs of the class. The most recent and largest meta-analysis [19] including SAVOR-TIMI 53 data also found the same trend towards increased risk of HF outcomes. Therefore, the findings of our analysis, as well as other recent studies, highlight the need for well-designed trials that rigorously assess for HF in patient with T2DM.
The possible mechanisms underlying the association of DPP4i with HF remain elusive [20]. However, interactions of DPP4i with HF cannot be totally ruled out, since levels of brain natriuretic peptides (BNP), which may be 100 times as high in patients with HF as in patients without HF, are known substrates of the enzyme DPP4 [21]. In addition, DPP4 is not specific to glucagon-like peptide 1 (GLP-1), and has the potential to mediate a wide range of both positive and negative pleiotropic effects independently of GLP-1 [22]. We speculate that reducing inactivated GLP-1, which has positive effects on myocardial function [23], or increasing other vasoactive substrates of DPP4 (e.g., BNP) could have detrimental effects during DPP4i treatment. Moreover, incretin-based therapies (mainly GLP-1 agonists) have been reported to increase heart rate in some studies, especially when used in conjunction with angiotensin-converting-enzyme inhibitor [24]. The increased heart rate may be secondary to the lower blood pressure induced by these agents but may also denote chronic (as opposed to acute, hypoglycemia-induced) activation of potentially adverse neurohormonal systems such as the sympathetic nervous system (SNS) [25]. Chronic SNS activation is a well-established contributor to the pathogenesis and progression HF in susceptible subjects. Lastly, as with all glucose-lowering agents, DPP4i may cause hypoglycemia (particularly when combined with other hypoglycemic agents), which is associated with short-term SNS activation. Whether repeated episodes of hypoglycemia contribute to deterioration in cardiac function, clinical HF, or both is uncertain [20].
The strengths of this study include the large population and the probable inclusion of all hospitalizations for HF because the NHIS is a compulsory and universal health care system in Korea. However, our study had several limitations. The database used was originally designed for billing purposes; therefore, inaccuracy in coding for HF and comorbidities may have occurred. Therefore, misdiagnosis and selective misclassification were possible. The main causes of HF remain unclear, and many important risk factors, clinical and physical findings, symptoms and signs, or disease severity were not available for adjustment or evaluation. We could not adjust for these confounding variables because of lack of data. Further study with full data regarding medications and co-existing illness is needed. We found that the increased hospitalization for HF in the first 30 days of DPP4i treatment was the same as that for pioglitazone. However, we must still be cautious in our interpretations and conclusions because causal inferences cannot be made on the basis of observational studies alone.
In conclusion, the present study shows that the increase in hospitalization for HF at days 0 to 30 for sitagliptin and vildagliptin was the same as that for pioglitazone. The differences between the drugs were not significant. The full spectrum of beneficial and adverse effects of DPP4i will not be known until long-term trials with clinical endpoints are complete. Therefore, we await the results of the ongoing trials with CVD as a main endpoint.

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

  • 1. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol 2014;10:293-302. ArticlePubMedPDF
  • 2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653. ArticlePubMedPMC
  • 3. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. American Diabetes Association. American College of Cardiology Foundation. American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192. ArticlePubMedPMCPDF
  • 4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412. ArticlePubMedPMC
  • 5. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795. PubMedPMC
  • 6. Nissen SE, Wolski K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-1201. PubMed
  • 7. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011;11:115-128. PubMed
  • 8. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008;359:1092-1095. ArticlePubMed
  • 9. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326. ArticlePubMed
  • 10. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. N Engl J Med 2013;369:1285-1287. ArticlePubMed
  • 11. Park C, Ha YC, Jang S, Jang S, Yoon HK, Lee YK. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab 2011;29:744-751. ArticlePubMedPDF
  • 12. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, Havranek EP, Heidenreich PA, Rutherford JD, Spertus JA, Stevenson LW, Goff DC, Grover FL, Malenka DJ, Peterson ED, Redberg RF. American College of Cardiology. American Heart Association Task Force on Clinical Data Standards. American College of Chest Physicians. International Society for Heart and Lung Transplantation. Heart Failure Society of America. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. Circulation 2005;112:1888-1916. ArticlePubMed
  • 13. Sachdeva A, Bavisetty S, Beckham G, Shen AY, Aharonian V, Mansukhani P, Stone GW, Leon M, Moses J, Moore N, Hyett R, Contreras R, Brar SS. Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention. J Am Coll Cardiol 2012;60:2357-2363. ArticlePubMed
  • 14. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2014;2:573-582. PubMed
  • 15. McMurray J. The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial In: Heart Failure Congress 2013; 2013 May 25-28; Lisbon, Portugal. Sophia Antipolis: European Society of Cardiology; 2013;pp 99.
  • 16. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-120. ArticlePubMed
  • 17. Iqbal N, Parker A, Frederich R, Donovan M, Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol 2014;13:33ArticlePubMedPMC
  • 18. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689-697. ArticlePubMed
  • 19. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014;32:147-158. ArticlePubMed
  • 20. Krum H, Skiba M, Wu S, Hopper I. Heart failure and dipeptidyl peptidase-4 inhibitors. Eur J Heart Fail 2014;16:603-607. ArticlePubMed
  • 21. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215. ArticlePubMedPMC
  • 22. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013;10:73-84. ArticlePubMedPDF
  • 23. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531. ArticlePubMedPDF
  • 24. Gustavson SM, Chen D, Somayaji V, Hudson K, Baltrukonis DJ, Singh J, Boyden TL, Calle RA. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:1056-1058. ArticlePubMed
  • 25. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010;56:728-733. ArticlePubMedPMC
Table 1

Clinical characteristics by treatment

dmj-39-247-i001.jpg
Characteristic Total Pioglitazone Sitagliptin Vildagliptin
Number 935,519 (100) 233,790 (25.0) 481,245 (51.4) 220,484 (23.6)
Age, yr 59.4±10.1 59.9±10.1 59.2±10.1 59.4±10.1
Sex, male/female 518,614/416,905 130,936/102,854 265,144/216,101 122,534/97,950
Follow-up, day 336.8±354.3 333.2±361.6 340.9±356.0 331.7±342.5

Values are presented as number (%) or mean±standard deviation.

Table 2

Incidence of hospitalization for heart failure for each drug

dmj-39-247-i002.jpg
Event Incidence rates/100,000 patient-yr
Total 0-360, day 0-30, day 31-360, day
Total 998 115.7 130.7 222.4 116.7
Pioglitazone 251 117.7 132.5 219.7 118.7
Sitagliptin 475 105.7 119.6 211.6 105.7
Vildagliptin 272 135.8 153.4 249.1 138.9
Table 3

Hazard ratio of hospitalization for heart failure in 0 to 30 days compared with 31 to 360 days

dmj-39-247-i003.jpg
HR 95% CI P value
Total 1.91 1.63-2.22 <0.001
Pioglitazone 1.85 1.34-2.53 0.001
Sitagliptin 2.00 1.60-2.49 <0.001
Vildagliptin 1.79 1.32-2.41 0.001

HR, hazard ratio; CI, confidence interval.

Table 4

Comparison of risk of hospitalization for heart failure among drugs

dmj-39-247-i004.jpg
Period Drugs HR 95% CI P value
0-360, day Pioglitazone 1
Sitagliptin 0.97 0.80-1.16 0.715
Vildagliptin 1.22 0.99-1.50 0.066
0-30, day Pioglitazone 1
Sitagliptin 1.02 0.69-1.49 0.931
Vildagliptin 1.19 0.77-1.84 0.441
31-360, day Pioglitazone 1
Sitagliptin 0.95 0.77-1.18 0.643
Vildagliptin 1.22 0.97-1.55 0.094

Adjusted for age and sex.

HR, hazard ratio; CI, confidence interval.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes
      Jui Wang, Hon-Yen Wu, Kuo-Liong Chien
      Diabetes & Metabolism.2022; 48(3): 101299.     CrossRef
    • Changing Fields-Diabetes Medications Invading the Cardiovascular Space
      Lauren D. Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P. Shah, Brandon E. Cave
      Current Problems in Cardiology.2021; 46(3): 100736.     CrossRef
    • Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2
      Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S. Aronow, William H. Frishman
      Cardiology in Review.2020; 28(5): 219.     CrossRef
    • Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
      Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang
      Cardiovascular Diabetology.2020;[Epub]     CrossRef
    • Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
      Kyoung Jin Kim, Jimi Choi, Juneyoung Lee, Jae Hyun Bae, Jee Hyun An, Hee Young Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim, Nam Hoon Kim
      Cardiovascular Diabetology.2019;[Epub]     CrossRef
    • Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
      Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
      Korean Circulation Journal.2018; 48(5): 395.     CrossRef
    • Worsening Heart Failure During the Use of DPP-4 Inhibitors
      Milton Packer
      JACC: Heart Failure.2018; 6(6): 445.     CrossRef
    • Resistance exercise improves cardiac function and mitochondrial efficiency in diabetic rat hearts
      Tae Hee Ko, Jubert C. Marquez, Hyoung Kyu Kim, Seung Hun Jeong, SungRyul Lee, Jae Boum Youm, In Sung Song, Dae Yun Seo, Hye Jin Kim, Du Nam Won, Kyoung Im Cho, Mun Gi Choi, Byoung Doo Rhee, Kyung Soo Ko, Nari Kim, Jong Chul Won, Jin Han
      Pflügers Archiv - European Journal of Physiology.2018; 470(2): 263.     CrossRef
    • Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?
      Milton Packer
      Circulation Research.2018; 122(7): 928.     CrossRef
    • Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes
      Hyouk-Jun Chin, Jin Hyun Nam, Eui-Kyung Lee, Ju-Young Shin
      Medicine.2017; 96(25): e7213.     CrossRef
    • Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction
      Nattayaporn Apaijai, Tharnwimol Inthachai, Suree Lekawanvijit, Siriporn C Chattipakorn, Nipon Chattipakorn
      Journal of Endocrinology.2016; 229(3): 245.     CrossRef
    • The current role of thiazolidinediones in diabetes management
      Christos V. Rizos, Anastazia Kei, Moses S. Elisaf
      Archives of Toxicology.2016; 90(8): 1861.     CrossRef
    • Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion
      Simón Quetzalcoatl Rodríguez-Lara, Ernesto German Cardona-Muñoz, Ernesto Javier Ramírez-Lizardo, Sylvia Elena Totsuka-Sutto, Araceli Castillo-Romero, Teresa Arcelia García-Cobián, Leonel García-Benavides
      Oxidative Medicine and Cellular Longevity.2016; 2016: 1.     CrossRef
    • Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors
      Teresa Vanessa Fiorentino, Giorgio Sesti
      Endocrine.2016; 53(2): 373.     CrossRef
    • Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J2015;39:247-52)
      Dae Ho Lee
      Diabetes & Metabolism Journal.2015; 39(4): 348.     CrossRef
    • Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J2015;39:247-52)
      Sunghwan Suh, Gi Hyeon Seo, Chang Hee Jung, Mee-Kyoung Kim, Sang-Man Jin, You-Cheol Hwang, Byung-Wan Lee, Jae Hyeon Kim
      Diabetes & Metabolism Journal.2015; 39(4): 350.     CrossRef
    • Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
      Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, Indra C Pieters, Djuna L Cahen, Michaela Diamant, Daniël H van Raalte
      BMJ Open.2015; 5(11): e009579.     CrossRef
    • Dipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?
      Yong-ho Lee
      Diabetes & Metabolism Journal.2015; 39(3): 204.     CrossRef

    • PubReader PubReader
    • Cite
      CITE
      export Copy
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
      Diabetes Metab J. 2015;39(3):247-252.   Published online April 22, 2015
      Close
    • XML DownloadXML Download

    Diabetes Metab J : Diabetes & Metabolism Journal